Fox Run Management L.L.C. Boosts Stock Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Fox Run Management L.L.C. lifted its position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 96.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 37,838 shares of the company’s stock after buying an additional 18,575 shares during the period. Fox Run Management L.L.C. owned about 0.10% of iTeos Therapeutics worth $291,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. State Street Corp grew its position in iTeos Therapeutics by 21.9% during the third quarter. State Street Corp now owns 1,175,353 shares of the company’s stock valued at $12,000,000 after acquiring an additional 211,452 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of iTeos Therapeutics by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 640,350 shares of the company’s stock valued at $6,540,000 after purchasing an additional 20,092 shares during the last quarter. JPMorgan Chase & Co. raised its position in iTeos Therapeutics by 1.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 467,319 shares of the company’s stock worth $4,771,000 after purchasing an additional 5,368 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in iTeos Therapeutics by 3.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 222,135 shares of the company’s stock worth $2,268,000 after purchasing an additional 8,397 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. boosted its position in iTeos Therapeutics by 16.8% during the third quarter. Jacobs Levy Equity Management Inc. now owns 205,863 shares of the company’s stock valued at $2,102,000 after buying an additional 29,549 shares during the period. 97.16% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently commented on ITOS. Wedbush reiterated an “outperform” rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a report on Wednesday, March 5th. JPMorgan Chase & Co. decreased their price target on iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating on the stock in a research note on Thursday, March 6th. Wells Fargo & Company lowered their price objective on iTeos Therapeutics from $19.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, March 6th. Finally, HC Wainwright restated a “buy” rating and issued a $46.00 target price on shares of iTeos Therapeutics in a report on Thursday, March 6th.

iTeos Therapeutics Price Performance

NASDAQ ITOS opened at $6.70 on Friday. iTeos Therapeutics, Inc. has a 1 year low of $6.32 and a 1 year high of $18.75. The stock has a market capitalization of $255.90 million, a PE ratio of -2.13 and a beta of 1.38. The business’s 50-day moving average is $7.30 and its 200 day moving average is $8.51.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings data on Wednesday, March 5th. The company reported ($1.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.13. As a group, equities research analysts anticipate that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current year.

iTeos Therapeutics Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.